Trial Profile

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolebrutinib (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Acronyms PERSEUS
Sponsors Sanofi; Sanofi Genzyme

Most Recent Events

07 Jan 2026 Status changed from active, no longer recruiting to completed.
15 Dec 2025 According to a Sanofi media release, tolebrutinib was provisionally approved in the United Arab Emirates in July 2025.
15 Dec 2025 According to a Sanofi media release, full safety and efficacy results will be presented at a forthcoming medical meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com